AlphaCentric Advisors’s Procept Biorobotics PRCT Stock Holding History

AlphaCentric Advisors’s Portfolio PRCT Stock Details PRCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$339K	Hold	15,000	–	–	0.29%	118
2026 Q1	$375K	Sell	15,000 -10,000	-40%	-$282K	0.37%	93
2025 Q4	$787K	Buy	+25,000	New	+$829K	0.78%	32
2024 Q4	$644K	Hold	8,000	–	–	0.64%	43
2024 Q3	$641K	Sell	8,000 -2,000	-20%	-$142K	0.48%	61
2024 Q2	$611K	Sell	10,000 -15,000	-60%	-$892K	0.45%	72
2024 Q1	$1.24M	Buy	+25,000	New	+$1.19M	0.75%	52
2023 Q4	–	Sell	-30,000	Closed	-$984K	–	275
2023 Q3	$984K	Sell	30,000 -20,000	-40%	-$682K	0.56%	63
2023 Q2	$1.77M	Hold	50,000	–	–	0.98%	36
2023 Q1	$1.42M	Hold	50,000	–	–	0.98%	28
2022 Q4	$2.08M	Hold	50,000	–	–	2.05%	5
2022 Q3	$2.07M	Buy	+50,000	New	+$1.99M	2.13%	7
2021 Q4	$875K	Buy	35,000 +15,000	+75%	+$555K	0.26%	38
2021 Q3	$763K	Buy	+20,000	New	+$768K	0.19%	45

Other funds holding PRCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

AlphaCentric Advisors's PRCT Position: Q2 2026 in Review

AlphaCentric Advisors held its Procept Biorobotics (PRCT) position steady in Q2 2026 at 15,000 shares worth $339K. The position accounts for 0.29% of the portfolio, ranked #118.

AlphaCentric Advisors first reported a position in PRCT in Q3 2021 and has held it in 14 quarters since. The position peaked at $2.08M in Q4 2022. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

AlphaCentric Advisors held 15,000 shares of Procept Biorobotics worth $339K as of Q2 2026.
AlphaCentric Advisors left its Procept Biorobotics share count unchanged in Q2 2026.
Procept Biorobotics made up 0.29% of AlphaCentric Advisors's portfolio in Q2 2026, its #118 holding.
AlphaCentric Advisors first reported a position in Procept Biorobotics in Q3 2021 and has held it in 14 quarters since.
AlphaCentric Advisors's Procept Biorobotics position peaked at $2.08M in Q4 2022.
254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.